Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03580707 · ClinicalTrials.gov registry record · Phase 2
Does BRV Have Faster Onset Time & Greater Effect Than LEV in Epilepsy Pts Using PPR Pharmacodynamic Efficacy Endpoint
A Phase 2 study of Photosensitive Epilepsy, sponsored by Rosenfeld, William E., M.D..
- Completed
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
- 1
- Study location
NCT03580707 is a Phase 2 study of Photosensitive Epilepsy that has completed, run by Rosenfeld, William E., M.D.. The registered enrollment target is 16 participants. The trial reports 1 study location across 1 state.
The verdict
NCT03580707, a Phase 2 study of Photosensitive Epilepsy, has completed, sponsored by Rosenfeld, William E., M.D..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
- 1
- Study location
Study Summary
The main purpose of this study is to see whether brivaracetam has a faster onset time and greater effect than levetiracetam in subjects with photosensitive seizures. Part 1 of the study will compare the effects of levetiracetam 1500 mg with the effects of brivaracetam 100 mg. Part 2, will compare the effects of levetiracetam 1500 mg with the effects of brivaracetam 100 mg or will compare the effects of levetiracetam 500mg with the effects of brivaracetam 25 mg.
Conditions Studied
Interventions
- DRUG BRV vs LEV in randomized double blinded, crossover fashion
Study Locations (1)
Missouri
- The Comprehensive Epilepsy Care Center For Children And Adults - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2018-06-01 |
| Est. Completion | 2018-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03580707
The ClinicalTrials.gov registry entry for NCT03580707 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rosenfeld, William E., M.D., which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Photosensitive Epilepsy appearing as the primary indexed condition, and to 1 intervention - of which BRV vs LEV in randomized double blinded, crossover fashion is the first listed.
NCT03580707 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.
Frequently Asked Questions
What is clinical trial NCT03580707 about?
NCT03580707 is a clinical study titled "Does BRV Have Faster Onset Time & Greater Effect Than LEV in Epilepsy Pts Using PPR Pharmacodynamic Efficacy Endpoint". The main purpose of this study is to see whether brivaracetam has a faster onset time and greater effect than levetiracetam in subjects with photosensitive seizures. Part 1 of the study will compare the effects of levetiracetam 1500 mg with the effects of brivaracetam 100 mg. Part 2, will compare th...
What is the current status of trial NCT03580707?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2018-06-01. Estimated completion is 2018-12-31.
What conditions does trial NCT03580707 study?
This clinical trial studies the following conditions: Photosensitive Epilepsy.
What interventions are being tested in trial NCT03580707?
The interventions under investigation include: BRV vs LEV in randomized double blinded, crossover fashion (DRUG).
Who is sponsoring clinical trial NCT03580707?
This trial is sponsored by Rosenfeld, William E., M.D., which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03580707 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.